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The hospital burden of disease associated with bone metastases and skeletal-related events in patients with
breast cancer, lung cancer, or prostate cancer in Spain
Metastatic bone disease (MBD) is the most common cause of cancer pain and of serious skeletal-related events
(SREs) reducing quality of life. Management of MBD involves a multimodal approach aimed at delaying the
ﬁrst SRE and reducing subsequent SREs. The objective of the study was to characterise the hospital burden of
disease associated with MBD and SREs following breast, lung and prostate cancer in Spain. Patients admitted
into a participating hospital, between 1 January 2003 and 31 December 2003, with one of the required cancers
were identiﬁed and selected for inclusion into the study. The index admission to hospital, incidence of patients
admitted and hospital length of stay were analysed. There were 28 162 patients identiﬁed with breast, lung and
prostate cancer. The 3 year incidence rates of hospital admission due to MBD were 95 per 1000 for breast
cancer, 156 per 1000 for lung cancer and 163 per 1000 for prostate cancer. For patients admitted following an
SRE, the incidence rates were 211 per 1000 for breast cancer, 260 per 1000 for lung cancer and 150 per 1000 for
prostate cancer. This study has shown that cancer patients consume progressively more hospital resources as
MBD and subsequent SREs develop.
Keywords: breast cancer, lung cancer, prostate cancer, metastases, skeletal-related events, burden of
disease.
INTRODUCTION
In the year 2002, there were approximately 162 000 new
cases of cancer diagnosed in Spain: approximately 97 800
in males and 64 000 in females (ratio 1.5:1) (Ferlay et al.
2004). The overall incidence for Spain can be considered
average for males and females with worldwide adjusted
rates of 307 and 179 new cases respectively per 100 000
inhabitants per year. This ranks behind North America,
Western Europe and Australia (López et al. 2005).
Overall, the most frequent cancer in Spain is colorectal
(approximately 26 000 new cases per year), followed by
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(13 500). Breast cancer is the most common cancer in
females, whereas in males the most common cancers are
lung and prostate cancer.
Within the European context, the cancer survival rate in
Spain is comparable with that of more developed coun-
tries and above the European average, regardless of cancer
type (Gatta & the EUROCARE Working Group 2003).
Overall, 44.0% of men, 56.4% of women, 76.4% of ado-
lescents (14–18 years) and 71.0% of children (0–14 years)
suffering from cancer in Spain, survived more than 5
years. The cancers with the worst prognosis are lung,
oesophagus, pancreas and liver, with a 5-year survival rate
at less than 20%, while breast, thyroid, bladder, mela-
noma, Hodgkin’s lymphoma, uterine and testicular have
the best prognosis with a 5-year survival at greater than
70%, and prostate cancer around 65% (Berrino & the
EUROCARE Working Group 2003). Survival has
improved by about 10% between the mid-1980s and the
1990s, and is expected to continue improving for most
cancers (National Center for Epidemiology 2002).
Cancer is the leading cause of death among men and
second among women, after cardiovascular diseases. In
2005, 96 499 people died in Spain from cancer, 60 701
males and 35 798 females (ratio 1.7:1) representing 25% of
all deaths. Approximately one in three men (30.3%) and
one in every ﬁve women (19.5%) die from cancer (López
et al. 2004).
METASTATIC BONE DISEASE AND
SKELETAL-RELATED EVENTS
Bone metastases are a frequent complication of cancer,
occurring in up to 70% of patients with advanced breast or
prostate cancer and in approximately 15–30% of patients
with lung, colon, stomach, bladder, uterus, rectum,
thyroid, or kidney cancer (Coleman & Rubens 1987;
Mundy 2002). Melanomas are other common cancers that
metastasise to bone. Furthermore, once cancer metasta-
sises to bone, it is usually incurable: only 20% of patients
with breast cancer are still alive 5 years after the discovery
of bone metastasis (Coleman 2001; Coleman & Seaman
2001).
Bone metastases are complicated by signiﬁcant morbid-
ity including skeletal-related events which are local irre-
versible changes and include pathological fracture, bone
surgery, radiation therapy to the bone and spinal cord
compression (Lorusso 2001; Coleman 2004; Lipton 2005;
Delea et al. 2006). These events are widely considered to
negatively affect quality of life (Lipton 2005; Wardley
et al. 2005; Clemons et al. 2006), and hence present a
challenge for the goals of palliative therapy, which include
managing these patients’ pain, preventing further deterio-
ration and preserving quality of life (McMillan 1996; Ito &
Tokudome 2006; Manders et al. 2006; Karamouzis et al.
2007).
Although the humanistic burden of skeletal-related
events has been studied, little research has focused on
the economic impact of these events, particularly in
Europe. In the Netherlands, Groot et al. (2003) conducted
hospital chart reviews of 28 patients with prostate cancer
and metastatic bone disease (MBD) to quantify the cost
associated with skeletal-related events. Costs and hospi-
tal length of stays varied by type of skeletal-related event
and ranged from €1187 to €40 948, depending on event
type.
The objective of the study was to characterise the hos-
pital burden of disease associated with bone metastases
and skeletal-related events following breast cancer, lung
cancer and prostate cancer in Spain.
METHODS
Data between 1 January 2000 and 31 March 2006 were
selected from the IASIST Conjunto Mínimo Básico de
Datos (CMBD – the Joint Basic Minimum Dataset) hospi-
tal activity database which collects inpatient episode data
for Spain. The database collects data on every hospital
admission at 187 of 268 public (n = 156) and private hos-
pitals (n = 31) across Spain. Patients with an index inpa-
tient admission identifying either female breast cancer
(ICD-9-CM 174*), lung cancer (ICD-9-CM 162*), or pros-
tate cancer (ICD-9-CM 185*) between the dates of 1
January 2003 and 31 December 2003 were selected from
CMBD. These patients were then traced back for 3 years (1
January 2000 to 31 December 2002), to identify incident
cancer cases by excluding any patients who had previously
been admitted with the same cancer. The remaining
patients were then followed forward until 31 March 2006
to identify those with MBD (ICD-9-CM 198.5*), and sub-
sequent skeletal-related events, speciﬁcally relating to
pathological fractures, spinal cord compressions, radiation
therapy, or bone surgery (Fig. 1), these were identiﬁed
using ICD-9-CM codes for diseases, and for procedures.
Patients who had an admission with bone metastases
prior to a cancer admission, or an admission with a
skeletal-related event prior to either an admission with
cancer, or bone metastases, and patients who had an
admission with a skeletal-related event but no admission
with bone metastases were excluded from the study. The
date of the index admission with cancer, bone metastases
or skeletal-related event was not necessarily the date of
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756diagnosis; however, for the purposes of this study it has
been used as a proxy for date of diagnosis.
Descriptive statistical analysis was conducted for
demographics within each cancer type to identify the
number of patients in each category, mean age and sex,
incidence rate for developing bone metastases following
initial admission for cancer, and incidence rate for
skeletal-related events following admission for bone
metastases. Furthermore, the patient’s hospital length of
stay by index admission and subsequent re-admission,
was analysed and described. Kaplan–Meier estimates
were determined with regard to inpatient admissions
for (1) time from index cancer to subsequent bone
metastases; (2) time from bone metastases to ﬁrst
skeletal-related event; (3) time from ﬁrst skeletal-related
event to second skeletal-related event; and (4) time from
second skeletal-related event to third skeletal-related
event. Mortalilty data were not available for this dataset
therefore only the time between admissions, and inci-
dence of disease development has been included as true
survival could not be calculated.
Finally, the cost for the index admission, and the cost of
the subsequent admissions was analysed by speciﬁc
disease stage and by cancer type. Each hospital has an
associated cost negotiated annually with central govern-
ment, while each medical procedure has a diagnosis-
related group relative weight. The procedure cost was
determined by multiplying the hospital cost by the
diagnosis-related group relative weight. The cost applies
to the admission and not necessarily to the treatment of
the disease, therefore, the cost for the index admission is
calculated using the admission where the cancer is ﬁrst
recorded, this was also the same for bone metastases and
skeletal-related events.
RESULTS
Between 1 January 2003 and 31 December 2003, there
were 1 550 557 unique patients in the IASIST CMBD data-
base, with 46 444 patients having a cancer admission and
28 162 with an index inpatient admission for either breast
cancer (n = 10 090), lung cancer (n = 10 526), or prostate
cancer (n = 7546) (Table 1). In these patients, the 3 year
incidence rate of hospital admission due to subsequent
bone metastases ranged from 95 per 1000 [95% conﬁdence
interval (CI) 89–101] for breast cancer, 156 per 1000 (95%
CI 149–164) for lung cancer, males 153 per 1000 (95% CI
145–161), and females 179 per 1000 (95% CI 157–203), and
163 per 1000 (95% CI 155–172) for prostate cancer. Fur-
thermore, the incidence rates for patients developing a
skeletal-related event, subsequent to MBD, were 211 per
1000 (95% CI 183–242) for breast cancer, 260 per 1000
(95% CI 236–285) for lung cancer (males 260 per 1000
(95% CI 234–288), and females 258 per 1000 (95% CI
198–332), and 150 per 1000 (95% CI 131–171) for prostate
cancer.
1 January  2000 –
31 December  2002
1 January  2003 –
31 December  2003
31 December  2003 –
31 March 2006
Pre-index period
￿No prior index cancer 
diagnosis code
￿No diagnosis code of 
MBD
￿No diagnosis code of 
SREs
Index period 
￿Inpatient breast 
cancer diagnosis 
code
￿Inpatient prostate 
cancer diagnosis 
code
￿Inpatient lung cancer 
diagnosis code
Follow-up period
￿Inpatient MBD 
diagnosis code
￿Inpatient SRE 
diagnosis code
Figure 1. Study schema. MBD, metastatic bone disease; SRE,
skeletal-related event.
Table 1. Annual number of patients presenting at secondary care with ﬁrst recorded cancer, bone metastases, or skeletal-related event
(SRE) clinical code
Cancer only
Cancer with bone
metastases only
Cancer with bone
metastases and SRE
Breast cancer
Number 9136 753 201
Mean age 60 62 61
Female 100% 100% 100%
Lung cancer
Number 8881 1218 427
Mean age 67 64 62
Male 87.8% 85.6% 85.7%
Female 12.2% 14.4% 14.3%
Prostate cancer
Number 6293 1031 221
Mean age 73 74 73
Male 100% 100% 100%
Hospital burden associated with MBD and SREs in Spain
© 2009 The Authors
European Journal of Cancer Care © 2009 Blackwell Publishing Ltd
757Length of stay
Patient length of hospital stay increased with the devel-
opment of bone metastases and skeletal-related events
(Fig. 2); this observation was consistent across cancer
types. The length of stay for the index admission was
greatest in those who subsequently developed skeletal-
related events (12–18 days), compared with those with the
cancer only (6–11 days) and cancer and MBD (9–11 days);
furthermore, follow-up attendances also had greater
length of stays in patients who subsequently developed
skeletal-related events (4–8 days), again compared with
those with the cancer only (2–7 days). Similarly, the
length of stay over 3 years across all related admissions
showed the same pattern with those developing skeletal-
related events having a far greater overall mean length of
stay (26–32 days) than those who developed no further
complications (8–15 days), or who developed MBD (18–22
days). Of those with skeletal-related events, the hospital
length of stay varied between event type with index
admissions averaging between 12 and 20 days, follow-up
admissions between 3 and 11 days, and overall length of
stay between 26 and 35 days (Table 2).
Stratifying the data by admission type (elective or emer-
gency) demonstrated the increase in 3-year length of stay
statistics attributable to bone metastases and skeletal-
related events was largely driven by patients with emer-
gency admissions (Fig. 3).
Re-admissions and survival
Patients with MBD and skeletal-related events generally
had a greater mean number of re-admissions to hospital
than those with cancer only. However, there was no dif-
ference in the number of readmissions between those
who developed bone metastases only and those who
developed MBD followed by a skeletal-related event. The
average number of re-admissions was one in patients
with breast, lung and prostate cancer only, while in
those with MBD the average number or re-admissions
was three, one and two, for breast, lung or prostate
cancer, respectively.
Cost
The pattern of costs was similar across breast and prostate
cancer types, showing that the cost of the admissions
Figure 2. Mean length of stay by disease
type and stage. SRE, skeletal-related
event.
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Table 2. Length of stay by skeletal-related event type
Index
Admission
Follow-up
Admission
All
Admissions
Breast cancer
Pathological fracture 16 5 31
Spinal cord
compression
14 9 27
Bone surgery 17 7 35
Radiation therapy 16 3 30
Lung cancer
Pathological fracture 20 7 32
Spinal cord
compression
15 7 28
Bone surgery 19 11 35
Radiation therapy 19 10 34
Prostate cancer
Pathological fracture 12 10 26
Spinal cord
compression
14 7 27
Bone surgery 12 11 29
Radiation therapy 13 7 27
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758increased as the disease progressed into MBD and subse-
quent skeletal-related events (Fig. 4). The average cost of
the index admission for those with breast cancer was
€2374 (SD €1216.58); with the average cost of the ﬁrst
admission with MBD increasing to €3515 (SD €1530.99);
and €3757 (SD €1420.89) for the ﬁrst admission with a
skeletal-related event, while for prostate cancer patients
the average costs were €3194 (SD €2509.68); €3180 (SD
€2081.85) and €3585 (SD €1538.82). In contrast, the index
admission cost for lung cancer patients was higher than
subsequent admissions for MBD or skeletal-related events
[€4994 (SD €3765.16), €4227 (SD €2037.45) and €4298 (SD
€1939.85), respectively].
DISCUSSION
It was shown that within 3 years of their index admission
9.5% of breast cancer patients, 15.6% of lung cancer
patients and 16.6% of prostate cancer patients were sub-
sequently admitted to secondary care for development of
bone metastases. Furthermore, 21.1% of these breast
cancer patients, 26.0% of these lung cancer patients and
17.7% of these prostate cancer patients later developed a
skeletal-related event requiring hospital admission.
As MBD and skeletal-related events are signs of progres-
sion in cancer patients, our ﬁndings, which indicate that
patients who develop MBD or subsequent skeletal-related
events are more health resource intensive when compared
with patients who have cancer only, is not unexpected.
Not only are their inpatient lengths of stay longer,
through their index and follow-up admissions, they are
also re-admitted more often. In addition, once a patient
has developed bone metastases and a skeletal-related
event, the risk for subsequent events increases with the
time between re-admissions for skeletal-related events
becoming shorter.
The associated cost of the index admission was gener-
ally increased for people who subsequently developed
MBD when compared with those who did not; however,
this cost increased further once the bone metastases had
developed. This was also observed in patients who devel-
oped skeletal-related events with the cost of treatment
increasing further again. This could be indicative of
patients who later develop MBD and skeletal-related
events having more advanced cancer at the index admis-
sion, with advancing cancer likely to lead to a longer
length of stay and a subsequent reduction in the quality of
life (Coleman 2001; Wardley et al. 2005; Weinfurt et al.
2005; DePuy et al. 2007), therefore requiring more care,
and the requirement for more complicated, and expensive,
medical and surgical procedures.
It has been shown previously that as cancer progresses
and becomes more advanced, quality of life decreases,
prognosis worsens and the cost of treatment increases
(Groot et al. 2003). This study conﬁrms that patients who
develop MBD subsequent to their index hospital admis-
sion for cancer are a greater burden to health service pro-
viders than those who have cancer only, and this burden
further increases in those who subsequently further
develop a skeletal-related event. By reducing the number
of patients with cancer from developing bone metastases,
and furthermore reducing the number who develop
skeletal-related events both the ﬁnancial and logistical
burden on health service providers could be greatly
reduced.
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Figure 3. Mean length of stay by disease type and admission
status. SRE, skeletal-related event. elective, emergency.
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759LIMITATIONS
As the study was undertaken using secondary care data, it
is prudent to be aware that limitations exist. As with all
databases such as IASIST’s CMBD, there is the potential
for miscoding to take place and therefore patients may
have been included or excluded when they should not
have been. Furthermore, patients have been included in
the study because of the presence of the speciﬁc disease
being recorded at that hospital attendance whether the
attendance was related to that disease or not, it is there-
fore also likely that the true date of diagnosis is earlier
than that recorded in the inpatient records, which has
been used as a proxy. Patient mortality is not included in
CMBD, therefore, patient re-admissions and survival to
further admissions may be skewed towards a better
prognosis.
Cancer care may have been provided in other settings,
such as by primary care providers, outpatient attendances,
or in hospitals not providing data to CMBD, therefore, it is
possible that the true incidence and costs of cancer is
being underestimated.
CONCLUSIONS
This study has shown that cancer patients consume pro-
gressively more hospital resources when they develop
bone metastases and subsequent skeletal-related events.
Reducing the incidence of MBD and skeletal-related
events may lead to less inpatient admissions, shorter
lengths of stay and smaller costs.
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